What types of bacteria are typically resistant to tigecycline?

What bacteria show the strongest resistance to tigecycline?

Tigecycline retains activity against most tetracycline-resistant strains because it evades the common efflux pumps and ribosomal-protection proteins that affect older tetracyclines. Still, certain species consistently test non-susceptible in surveillance data. The clearest examples are Proteus mirabilis, Proteus vulgaris, Morganella morganii, and Providencia species, where intrinsic or acquired efflux mechanisms push minimum inhibitory concentrations above the susceptibility breakpoint. Pseudomonas aeruginosa is almost universally resistant for the same reason.

How common is resistance among Gram-positive pathogens?

Most Enterococcus faecalis and Enterococcus faecium isolates remain susceptible, yet vancomycin-resistant enterococci (VRE) can acquire additional tet genes that reduce tigecycline activity. Among staphylococci, methicillin-resistant Staphylococcus aureus (MRSA) isolates are usually susceptible, but occasional reports document MIC creep linked to overexpression of the mepA efflux pump. Streptococcus pneumoniae and other streptococci are almost always susceptible.

Which Gram-negative organisms develop acquired resistance most readily?

Acinetobacter baumannii and carbapenem-resistant Klebsiella pneumoniae are the Gram-negatives most frequently linked to rising tigecycline MICs. Resistance in these organisms usually stems from overexpression of RND-family efflux pumps (AcrAB-TolC or AdeABC) or, less often, ribosomal-protection proteins encoded by tet(X) variants. Enterobacter cloacae and Serratia marcescens show intermediate rates of non-susceptibility driven by the same pumps.

What mechanisms drive tigecycline non-susceptibility?

The dominant routes are (1) over-expression of chromosomally encoded efflux systems, (2) plasmid-borne tet(X) genes that chemically modify the molecule, and (3) mutations that alter the 30S ribosomal binding site. Horizontal transfer of tet(X) has been documented in both environmental and clinical isolates, raising concern about rapid spread under selective pressure.

When is tigecycline still the preferred agent despite resistance trends?

In complicated skin and intra-abdominal infections caused by susceptible MDR Gram-negatives or VRE, tigecycline retains clinical utility because few oral alternatives exist. Its lack of activity against Pseudomonas and Proteus means it is rarely chosen empirically for those organisms.

Are there approved or pipeline competitors that bypass these resistance patterns?

Eravacycline and omadacycline, both newer tetracycline-class agents, retain activity against many tet(X)-carrying strains and show lower MICs against Acinetobacter and Klebsiella isolates that test non-susceptible to tigecycline. Their clinical adoption is still limited by cost and narrower indications.

When does the tigecycline patent expire and who supplies generics?

The composition-of-matter patent for tigecycline expired in 2015 in the United States; multiple generic manufacturers now market the intravenous formulation. DrugPatentWatch.com tracks remaining formulation and method-of-use patents that could affect launch timing in certain markets.